Market Overview

UPDATE: Canaccord Genuity Initiates Synageva BioPharma at Buy, $60 PT; Attractive Orphan Platform

Share:
Related GEVA
22 Stocks With Three-Day Increasing Volume
Ultragenyx Downgraded At Morgan Stanley, Valuation 'Stretched' And Pipeline Faces Execution Risk

Canaccord Genuity initiates its coverage on Synageva BioPharma (NASDAQ: GEVA) with a Buy rating and a price target of $90.

Canaccord Genuity says, "Early but encouraging SBC--102 proof --102 proof--of --of- ofof-concept data: --concept data: The lateonset LAL-D Phase 1/2 trial data presented to date has been impressive – rapid and significant decreases in hepatic enzymes indicate that SBC-102 is having the predicted biochemical role in combating liver abnormalities."

GEVA closed at $38.50 on Friday.

Latest Ratings for GEVA

DateFirmActionFromTo
May 2015BairdDowngradesOutperformNeutral
Mar 2015JP MorganDowngradesOverweightNeutral
Feb 2015CitigroupMaintainsNeutral

View More Analyst Ratings for GEVA
View the Latest Analyst Ratings

Posted-In: Canaccord GenuityAnalyst Color Price Target Initiation Pre-Market Outlook Analyst Ratings

 

Related Articles (GEVA)

View Comments and Join the Discussion!